ASCO GI 2023: Zolbetuximab Plus mFOLFOX6 For Certain Patients With Advanced Gastric Cancers
Posted: 02/08/2023 | By: Melissa E. Fryman, MS

The SPOTLIGHT study’s phase III findings on zolbetuximab plus mFOLFOX6 as first-line treatment for patients with the biomarker claudin-18.2–positive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma were presented by Shitara et al at the 2023 ASCO Gastrointestinal Cancers Symposium (Abstract LBA292).

Question 1 of 5

Zolbetuximab targets CLDN18.2, which is a claudin. What type of protein is claudin?

Choose 1